- Current report filing (8-K)
November 09 2009 - 6:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
November 5,
2009
BRUKER
CORPORATION
(Exact name of
registrant as specified in its charter)
Delaware
(State or other
jurisdiction
of incorporation)
|
|
000-30833
(Commission
File Number)
|
|
04-3110160
(IRS Employer
Identification No.)
|
40
Manning Road
Billerica, MA 01821
(Address of principal
executive offices)(Zip Code)
Registrants telephone
number, including area code:
(978) 663-3660
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 of the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(c) On November 5, 2009, the Board
of Directors of Bruker Corporation (the Company) approved certain changes to
the Companys executive management team, to be effective February 1, 2010.
William J. Knight, 60, currently Chief Financial
Officer, will become Chief Operating Officer and will no longer serve as Chief
Financial Officer. Mr. Knight
joined the Company as Chief Financial Officer in October 2004. Before
joining the Company, Mr. Knight served as Chief Financial Officer of Anika
Therapeutics, Inc. from 2002 to 2004, as Chief Financial Officer of Zycos, Inc.
from 2000 to 2002, and as Chief Financial Officer of NMT Medical, Inc.
from 1998 to 2000. Mr. Knight is a
Certified Public Accountant and holds a B.B.A. in Accounting from the
University of Wisconsin.
Brian P. Monahan, 38, currently Chief Accounting
Officer and Vice President of Finance, will become Chief Financial Officer and
will also retain his role as the Companys principal accounting officer. Mr. Monahan joined the Company in April 2004
as Corporate Controller and was appointed Chief Accounting Officer and Vice
President of Finance in March 2009. In addition to his corporate
responsibilities, Mr. Monahan has served in various financial and
operational roles at the Companys Bruker Daltonics division. Before joining the Company, Mr. Monahan
served as Manager of Accounting and Financial Reporting at Fisher Scientific
International, Inc. from December 2002 through April 2004 and as
an audit manager for PricewaterhouseCoopers LLP from July 1999 through December 2002. Mr. Monahan is a Certified Public
Accountant and holds a B.S. in Accounting from the University of Massachusetts.
A copy of the press release announcing these appointments
is attached as Exhibit 99.1 to this report.
(e) On November 5, 2009, the Boards
Compensation Committee approved an increase to Mr. Knights annual salary
from $288,000 to $355,000 and an increase to Mr. Monahans annual salary
from $180,000 to $275,000, both increases to be effective immediately. The Compensation Committee also approved
awards to each of Mr. Knight and Mr. Monahan of options to purchase
50,000 shares and 100,000 shares, respectively, of the Companys common
stock. The options, granted on November 5,
2009, are exercisable at the closing price of the Companys common stock on the
grant date, subject to a five-year vesting schedule. Additionally, the Company will enter into
severance agreements with each of Mr. Knight and Mr. Monahan,
pursuant to which the officers will be entitled to severance payments equal to
six months salary in the event of termination of employment without cause.
Item 9.01. Financial Statements and Exhibits.
(d)
|
Exhibits
|
|
|
|
Number
|
|
|
|
|
99.1
|
Press release dated November 9, 2009.
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
BRUKER CORPORATION
|
|
(Registrant)
|
|
|
Date: November 9, 2009
|
By:
|
/s/Frank H. Laukien
|
|
|
Frank H. Laukien, Ph.D.
|
|
|
President
and
Chief Executive Officer
|
3
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024